Organon & Co. (NYSE:OGN) currently has a daily average trading volume of 2.08M but it saw 4517752 shares traded on Thursday. With a market cap of 5.08B USD, stock’s current market price of $19.86 came falling about -1.29 while comparing to the previous closing price of $20.12. In past 52 weeks, the stock remained buoying in the range of price level as high as $39.09 and as low as $19.87. In the recent trading on the day, stock has struck highest price mark of $19.93 while lowest mark touched by it was $19.15.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Taking a look at 20-day trading activity of Organon & Co. (OGN) gives us an average price of $21.63, while its current price level is -49.19% below from 52-week high level whereas it is -0.05% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $22.55 while that of 200 days or SMA-200 reads an average of $25.98. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.21% during that period while stretching the period over a month that decreases to 3.10%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.94 which implies that the stock is in oversold territory.
Organon & Co. (OGN)’s stock is currently under the radar of 10 analysts who are in consensus at a 12-month price target range of between $23.00 and $43.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $23.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $43.00. Average price target assigned by them is $30.75 which highlights an upside potential of 35.41% for the stock over that period. And to attain the median price target of $29.50 assigned by those analysts, stock has to add about 32.68% of value to its current levels.
Data by FactSet Research shows that 10 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 5 analysts suggested the investors to Buy the stock while 4 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Moderate Buy.
Over the week, OGN’s stock price is moving -2.98% down while it is -16.20% when we observe its performance for the past one month. Year-to-date it is -28.89% down and over the past year, the stock is showing a downside performance of -47.07%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of $1.08 beaten by the consensus estimate of $1.16 for the same. The company is expected to be releasing its next quarterly report in 08/10/2023, for which analysts forecasted an EPS of $1.03 while estimate for next year EPS is $4.3. For OGN, analysts are forecasting an EPS-growth rate of -14.50% for current year and estimate for EPS growth in next year is 6.30%. In next quarter, company is expected to be making quarterly sales of $1.57 billion as analysts are expecting the sales for current fiscal year at $6.3 billion and seeing the company making $6.46 billion in sales next year. Moreover, analysts are in estimates of $1.59 billion for current-quarter revenue.
Currently, Organon & Co.’s total number of outstanding shares is 254.39M with 0.08% of that held by the insiders while 80.05% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 11.40% and return on equity (ROE) at -77.90%. It has a price to earnings ratio (P/E ratio) of 6.80 while having a 4.34 of forward P/E ratio. Stock has a price to sale or P/S ratio amounts to 0.83. Its return on asset (ROA) is 7.00% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Vanguard Total Stock Market ETF came shrinking its share ownership by 0.44% in the Organon & Co. (OGN) increasing its stake to 3.11% with control over 34618.0 shares in the company. As per SEC documents, Vanguard Total Stock Market ETF shunned 7,916,358 of company’s common stock of worth $194.98 million as per recent closing price of the stock. Vanguard Total Stock Market ETF is not the only institutional holder which restructured its stake in Organon & Co., as Vanguard Small Cap Index Fund dumped 6,654,904 shares of worth $163.91 million to bring its holdings to a total of 1626.0 shares. In the most recent quarter, Vanguard 500 Index Fund came rising its stake by 0.54% in the company and now holds 5.98 million or 2.35% of the company’s stake having worth of about 147.25 million.
Leave a Reply